Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 4, 2013, Pages 487-495

  Rincón, Diego ^a,b,e   Lo Iacono, Oreste ^a   Tejedor, Marta ^c   Hernando, Ana ^a,e   Ripoll, Cristina ^a,b,e   Catalina, María Vega ^a,b,e   Salcedo, Magdalena ^a,b,e   Matilla, Ana ^a,b,e   Senosiain, María ^a,e   Clemente, Gerardo ^a,b,e   Molinero, Luis Miguel ^d   Albillos, Agustín ^b,c   Bañares, Rafael ^a,b,e,f,g  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d ALCE Ingeniería   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^g UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Chronic hepatitis C; Cirrhosis; Hepatic venous pressure gradient; Portal hypertension

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BOOTSTRAPPING; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; ESOPHAGUS VARICES; FEMALE; HEMODYNAMICS; HEPATIC VENOUS PRESSURE GRADIENT; HEPATITIS C; HEPATOBILIARY PARAMETERS; HUMAN; LIVER CIRCULATION; LIVER PERFUSION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATIC VEINS; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; VENOUS PRESSURE;

EID: 84875424620     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.711848     Document Type: Article

References (41)

1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
4. Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008;134: 1715-28.
5. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
6. Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626-31.
7. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-24.
8. Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007;102:1116-26.
9. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902-8.
10. Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzalez B, Minana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004;40:757-65.
11. Ripoll C, Banares R, Rincon D, Catalina MV, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology 2005;42:793-801.
12. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
13. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31.
14. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-8.
15. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004;39:280-2.
16. Ratti L, Pozzi M, Bosch J. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Dig Liver Dis 2005;37:886-93.
17. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Stat Med 1989;8:771-83.
18. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774-81.
19. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23: 2109-23.
20. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105.
21. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48(Suppl 1): S68-92.
22. JPoordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MSet al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
23. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
24. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
25. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCVgenotype 1 infection.NEngl JMed 2011;364:1207-17.
26. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
27. Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008;103:2747-56.
28. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61.
29. Ananth CV, Kleinbaum DG. Regression models for ordinal responses: a review of methods and applications. Int J Epidemiol 1997;26:1323-33.
30. Bressler B, Pinto R, El-Ashry D, Heathcote EJ. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut 2005;54:407-10.
31. Abraldes JG, Villanueva C, Banares R, Aracil C, Catalina MV, Garci APJC, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008;48:229-36.
32. Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009;9:31.
33. Fernandez-Rodriguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincon D, et al. Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response. Am J Gastroenterol 2010;105:2164-72.
34. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005;41: 1211-19.
35. Evans TW. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002;16(Suppl 5):6-11.
36. Banares R, Alonso S, Catalina MV, Casado M, Rincon D, Salcedo M, et al. Randomized controlled trial of aspiration needle versus automated biopsy device for transjugular liver biopsy. J Vasc Interv Radiol 2001;12:583-7.
37. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50: 923-8.
38. Rincon D, Ripoll C, Lo Iacono O, Salcedo M, Catalina MV, Alvarez E, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006;101: 2269-74.
39. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573-82.
40. Berzigotti A, Gilabert R, Abraldes JG, Nicolau C, Bru C, Bosch J, et al. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am J Gastroenterol 2008;103: 1159-67.
41. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290-7.